In last trading session, Inhibrx Inc. (NASDAQ:INBX) saw 0.23 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $29.44 trading at -$0.56 or -1.87% at ring of the bell on the day assigns it a market valuation of $1.29B. That closing price of INBX’s stock is at a discount of -56.22% from its 52-week high price of $45.99 and is indicating a premium of 73.95% from its 52-week low price of $7.67. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.55 million shares which gives us an average trading volume of 782.11K if we extend that period to 3-months.
Inhibrx Inc. (NASDAQ:INBX) trade information
Upright in the red during last session for losing -1.87%, in the last five days INBX remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $29.44 price level, adding 10.63% to its value on the day. Inhibrx Inc.’s shares saw a change of -32.59% in year-to-date performance and have moved -10.79% in past 5-day. Inhibrx Inc. (NASDAQ:INBX) showed a performance of -6.12% in past 30-days. Number of shares sold short was 3.96 million shares which calculate 3.12 days to cover the short interests.
Inhibrx Inc. (INBX) estimates and forecasts
Statistics highlight that Inhibrx Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 134.21% of value to its shares in past 6 months, showing an annual growth rate of -51.16% while that of industry is 4.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -74.10% in the current quarter and calculating -74.50% decrease in the next quarter. This year revenue growth is estimated to fall -42.30% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $630k for the same. And 3 analysts are in estimates of company making revenue of $750k in the next quarter that will end on Dec 2022. Company posted $2.53 million and $2.86 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -75.10% while estimating it to be -73.70% for the next quarter.
Inhibrx Inc. is more likely to be releasing its next quarterly report between November 07 and November 11 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Inhibrx Inc. (NASDAQ:INBX)’s Major holders
Insiders are in possession of 31.49% of company’s total shares while institution are holding 80.27 percent of that, with stock having share float percentage of 117.16%. Investors also watch the number of corporate investors in a company very closely, which is 80.27% institutions for Inhibrx Inc. that are currently holding shares of the company. Viking Global Investors, L.P. is the top institutional holder at INBX for having 5.31 million shares of worth $60.22 million. And as of Jun 29, 2022, it was holding 13.58% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 1.98 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 5.06% of outstanding shares, having a total worth of $22.44 million.
On the other hand, Smallcap World Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 1.63 million shares of worth $18.52 million or 4.18% of the total outstanding shares. The later fund manager was in possession of 1.44 million shares on Sep 29, 2022, making its stake of worth around $25.89 million in the company or a holder of 3.69% of company’s stock.